Výsledky vyhledávání - "Kayti Aviano"

Abstract CT154: Combination of cinrebafusp alfa with ramucirumab and paclitaxel is well tolerated and elicits encouraging clinical activity in patients with HER2-positive gastric/gastroesophageal junction (GEJ) adenocarcinoma

Autor: Geoffrey Ku, Jeeyun Lee, Kayti Aviano, Tim Demuth, Laura-Carolin Hasenkamp, Shane A. Olwill

Publikováno v: Cancer Research. 83:CT154-CT154

Introduction: Cinrebafusp alfa is a first-in-class bispecific antibody-Anticalin® fusion protein that targets HER2 and the costimulatory receptor 4-1BB, leading to enhanced activation of T cells in the tumor, while avoiding liver toxicity. In a Phas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d19984bfa95f0a495960a40c9e834bf9
https://doi.org/10.1158/1538-7445.am2023-ct154

Zobrazit plný text záznamu

Abstract CT017: Clinical and biomarker activity of PRS-343, a bispecific fusion protein targeting 4-1BB and HER2, from a phase 1 study in patients with advanced solid tumors (Study PRS-343-PCS_04_16)

Autor: Lynn Mar, Geoffrey Y. Ku, Sara A. Hurvitz, Markus Zettl, Patrick Jolicoeur, Paula R. Pohlmann, Corinna Schlosser, Johanna C. Bendell, Kayti Aviano, Rachna T. Shroff, Anuradha Krishnamurthy, Naimish Pandya, Aizea Morales Kastresana, Anthony W. Tolcher, Ingmar Bruns, Alice Bexon, Sarina Anne Piha-Paul, Shane Olwill

Publikováno v: Clinical Trials.

The authors did not submit an updated abstract. The original abstract should be considered final. Citation Format: Sarina Piha-Paul, Johanna C. Bendell, Anthony Tolcher, Rachna Shroff, Paula R. Pohlmann, Sara A. Hurvitz, Anuradha Krishnamurthy, Naimi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::60501a12ad838b25b9995545725ae771
https://doi.org/10.1158/1538-7445.am2021-ct017

Zobrazit plný text záznamu

Abstract CT122: A phase 2, multi-center, open-label study of cinrebafusp alfa (PRS-343) in combination with ramucirumab and paclitaxel in patients with HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma and in combination with tucatinib in patients with HER2 low gastric or gastroesophageal junction (GEJ) adenocarcinoma

Autor: Sarina A. Piha-Paul, Mukul Gupta, Do-Youn Oh, Yeul Hong Kim, Sun Young Rha, Yoon-Koo Kang, Marc Diez Garcia, Tania Fleitas Kanonnikoff, Virginia Arrazubi Arrula, Kayti Aviano, Tim Demuth, Geoffrey Ku

Publikováno v: Cancer Research. 82:CT122-CT122

Background: For patients (pts) with HER2-overexpressing metastatic gastric cancer, trastuzumab + chemotherapy +/- pembrolizumab is a standard first-line option but only provides an incremental overall survival (OS) benefit vs chemotherapy. Anticalin�

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1ad91d8896eb796974c3382122b41177
https://doi.org/10.1158/1538-7445.am2022-ct122

Zobrazit plný text záznamu

O82 A phase 1 dose escalation study of PRS-343, a HER2/4–1BB bispecific molecule, in patients with HER2-positive malignancies

Autor: Shane A. Olwill, Amita Patnaik, Rachna T. Shroff, Sara A. Hurvitz, Louis Matis, Anthony W. Tolcher, Markus Zettl, Geoffrey Y. Ku, Sarina Anne Piha-Paul, Paula R. Pohlmann, Manuela Duerr, Johanna C. Bendell, Ingmar Bruns, Rushdia Zareen Yusuf, Noah Hahn, Kayti Aviano, Anuradha Krishnamurthy, Jian Mei

Publikováno v: Oral Presentations.

Background Anticalin® proteins are recombinantly engineered human proteins based on lipocalins. PRS-343 is a first-in-class bispecific antibody-Anticalin fusion protein targeting the oncogenic tumor antigen HER2 and the costimulatory immune receptor

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2a42ae02a6e1d4b14c3ad5af6ebed4e6
https://doi.org/10.1136/lba2019.2

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání